This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety,
tolerability, PK, and antitumor activity of PRO1107 in patients with advanced solid tumors.
This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B:
tumor specific expansion.